EGFR-TKI SENSITIZING MUTATION
Clinical trials for EGFR-TKI SENSITIZING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR-TKI SENSITIZING MUTATION trials appear
Sign up with your email to follow new studies for EGFR-TKI SENSITIZING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer patients with brain-spread disease
Disease control Not yet recruitingThis phase 2 trial tests a combination of the drug zorifertinib plus chemotherapy delivered directly into the fluid around the brain and spine. It is for people with a specific type of lung cancer (NSCLC with EGFR mutation) whose cancer has spread to the lining of the brain and s…
Matched conditions: EGFR-TKI SENSITIZING MUTATION
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a dose increase control lung cancer that Isn't shrinking?
Disease control Not yet recruitingThis study tests whether a higher dose (160 mg) of the drug firmonertinib can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer whose tumors have stayed stable but not shrunk after 8 weeks on the standard 80 mg dose. About 28 adults aged 18-75 with …
Matched conditions: EGFR-TKI SENSITIZING MUTATION
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC